1. Home
  2. NPV vs MGNX Comparison

NPV vs MGNX Comparison

Compare NPV & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Virginia Quality Municipal Income Fund

NPV

Nuveen Virginia Quality Municipal Income Fund

HOLD

Current Price

$10.59

Market Cap

223.2M

Sector

Finance

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$4.04

Market Cap

256.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NPV
MGNX
Founded
1993
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
223.2M
256.8M
IPO Year
1995
2013

Fundamental Metrics

Financial Performance
Metric
NPV
MGNX
Price
$10.59
$4.04
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
79.0K
641.7K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
3.90%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$149,500,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$3.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.07
$1.30
52 Week High
$11.81
$5.08

Technical Indicators

Market Signals
Indicator
NPV
MGNX
Relative Strength Index (RSI) 30.65 52.68
Support Level $10.07 $3.81
Resistance Level $11.32 $4.38
Average True Range (ATR) 0.15 0.20
MACD -0.00 0.04
Stochastic Oscillator 64.65 78.06

Price Performance

Historical Comparison
NPV
MGNX

About NPV Nuveen Virginia Quality Municipal Income Fund

Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities. Company mostly invest in Education and Civic Organizations, Tax Obligation/General, Healthcare, Utilities , Housing/Multifamily, Transportation, and Others.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: